CIK 0001582313
- Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- Operating
- EIN
- 980661854
- Phone
- +1 604-484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-03-27 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Series 1 Preferred Shares | +1,338,000 | 1,338,000 | ||
| 2018-03-27 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Series 1 Preferred Shares | +861,000 | 861,000 | ||
| 2018-03-27 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Series 1 Preferred Shares | +238,000 | 238,000 | ||
| 2018-03-19 | AYCARDI-FONSECA ERNESTO Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2018-03-15 | ROBIN SHERRINGTON EVP Bus. & Corp. Development | Exercise or conversion | +3,086 | $3.77 | $12K | 7,820 |
| 2018-03-15 | ROBIN SHERRINGTON EVP Bus. & Corp. Development | Shares withheld for taxes | −1,928 | $4.63 | $9K | 5,892 |
| 2018-03-15 | ROBIN SHERRINGTON EVP Bus. & Corp. Development | Exercise or conversion · Stock Option (Right to Buy) | −3,086 | 0 | ||
| 2018-03-14 | HOLLER FRANK A Director | Exercise or conversion | +3,086 | $3.77 | $12K | 118,955 |
| 2018-03-14 | HOLLER FRANK A Director | Exercise or conversion · Stock Option (Right to Buy) | −3,086 | 0 | ||
| 2018-03-12 | PIMSTONE SIMON N. CEO | Exercise or conversion | +10,288 | $3.77 | $39K | 228,135 |
| 2018-03-12 | PIMSTONE SIMON N. CEO | Exercise or conversion · Stock Option (Right to Buy) | −10,288 | 0 | ||
| 2018-03-12 | COHEN CHARLES J. VP, Biology | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-03-12 | EMPFIELD JAMES R. SVP, Drug Discovery | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2018-03-12 | ROBIN SHERRINGTON EVP Bus. & Corp. Development | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2018-03-12 | MORTIMER IAN PRESIDENT & CFO | Grant or award · Stock Option (Right to Buy) | +105,000 | 105,000 | ||
| 2018-03-12 | PIMSTONE SIMON N. CEO | Grant or award · Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2018-02-22 | Hayden Michael R Director | Gift | −29,580 | 131,607 | ||
| 2018-02-22 | Hayden Michael R Director | Gift | +21,180 | 97,066 | ||
| 2018-02-12 | COHEN CHARLES J. VP, Biology | Exercise or conversion | +26,748 | $3.71 | $99K | 26,748 |
| 2018-02-12 | COHEN CHARLES J. VP, Biology | Shares withheld for taxes | −22,669 | $3.50 | $79K | 4,079 |
Page 28 of 42 · 836 trades